Verition Fund Management LLC Buys 951,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Verition Fund Management LLC grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 172.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,504,320 shares of the company's stock after purchasing an additional 951,500 shares during the period. Verition Fund Management LLC owned about 2.12% of Zentalis Pharmaceuticals worth $5,536,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. GSA Capital Partners LLP boosted its holdings in Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock worth $2,240,000 after purchasing an additional 353,384 shares in the last quarter. Decheng Capital LLC raised its holdings in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company's stock worth $12,558,000 after acquiring an additional 970,859 shares during the period. XTX Topco Ltd lifted its position in Zentalis Pharmaceuticals by 1,581.9% during the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company's stock worth $730,000 after acquiring an additional 167,854 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Zentalis Pharmaceuticals by 152.6% during the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock valued at $2,706,000 after acquiring an additional 399,745 shares during the period. Finally, Primecap Management Co. CA grew its position in shares of Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock valued at $5,513,000 after purchasing an additional 265,690 shares during the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock traded down $0.30 during trading hours on Tuesday, reaching $3.36. The company had a trading volume of 1,176,895 shares, compared to its average volume of 1,314,309. Zentalis Pharmaceuticals, Inc. has a 1-year low of $2.66 and a 1-year high of $18.07. The company has a 50 day moving average of $3.36 and a 200 day moving average of $4.72.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. Equities research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Guggenheim decreased their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Oppenheimer restated an "outperform" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 price target on the stock in a research report on Monday, August 12th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $10.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.